 Connection
Virginia Borges to Drug Administration Schedule
This is a "connection" page, showing publications Virginia Borges has written about Drug Administration Schedule.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.207 |
|
|
|
-
Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2018 09 01; 4(9):1214-1220.
Score: 0.127
-
Come SE, Borges VF. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer. 2005 Apr; 6 Suppl 1:S15-22.
Score: 0.050
-
Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 07; 19(7):880-888.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|